bexirestrant (SCO-120) / Sun Pharma Advanced Research Company - LARVOL DELTA

A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Sun Pharma Advanced Research Company Limited | N=167 ➔ 9 | Trial completion date: Jan 2024 ➔ Feb 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2024 ➔ Feb 2023; The decision to close is due commercial reasons only

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: Sun Pharma Advanced Research Company Limited | Active, not recruiting ➔ Completed | Trial completion date: Feb 2023 ➔ Oct 2022 | Trial primary completion date: May 2022 ➔ Oct 2022

Trial completion • Trial completion date • Trial primary completion date

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Trial completion date: Nov 2022 ➔ Feb 2023

Trial completion date

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Trial completion date: Aug 2022 ➔ Oct 2022

Trial completion date

A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=141 | Recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=141 | Not yet recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Initiation date: Jan 2022 ➔ Apr 2022

Trial initiation date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Sun Pharma Advanced Research Company Limited | Trial completion date: Mar 2022 ➔ Jun 2022 | Trial primary completion date: Mar 2022 ➔ Jun 2022

Trial completion date • Trial primary completion date

A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1; N=141; Not yet recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; Initiation date: Oct 2021 ➔ Jan 2022

Clinical • Trial initiation date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1; N=132; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; Trial completion date: Jul 2021 ➔ Mar 2022; Trial primary completion date: Jul 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date

A Study in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1; N=141; Not yet recruiting; Sponsor: Sun Pharma Advanced Research Company Limited

Clinical • New P1 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects (clinicaltrials.gov) - P1; N=132; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; N=76 ➔ 132

Clinical • Enrollment change

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Postmenopausal Female Volunteers (clinicaltrials.gov) - P1; N=76; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; Trial completion date: Nov 2020 ➔ Jun 2021; Trial primary completion date: Nov 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Postmenopausal Female Volunteers (clinicaltrials.gov) - P1; N=76; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; N=50 ➔ 76

Clinical • Enrollment change

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Postmenopausal Female Volunteers (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; Trial completion date: Apr 2020 ➔ Sep 2020; Trial primary completion date: Apr 2020 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Postmenopausal Female Volunteers (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Sun Pharma Advanced Research Company Limited; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open